Related Experiment Video
Updated: Jul 13, 2026

Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
Published on: February 17, 2016
Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications
Juliene K G Co1, Saguna Verma, Ulziijargal Gurjav
1Retrovirology Research Laboratory, Department of Tropical Medicine, Medical Microbiology and Pharmacology, Asia-Pacific Institute of Tropical Medicine and Infectious Diseases, John A. Burns School of Medicine, Honolulu, HI 96813, USA.
Abstract:
One of the major limitations of highly active antiretroviral therapy is its inability to inhibit the replication of polyomavirus JC (JCV), the etiologic agent of progressive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness. We previously demonstrated the induction of interferon (IFN)-stimulated genes (ISGs) by JCV. In the present study, we characterize the specific viral events required to induce ISGs and the potential antiviral effects of type I IFN on JCV replication in human fetal glial cells in the presence and absence of type I IFNs. Productive JCV replication was essential for the induction of the antiviral host response. JCV replication at all steps was significantly inhibited in the presence of IFN, and neutralizing anti-IFN antibody rescued the inhibitory effect of IFN. These results support the use of IFN as an adjunct therapy for patients with PML. Because IFN cannot cross the blood-brain barrier to achieve its direct antiviral effect, intrathecal administration of IFN is warranted.
Insights
Highly active antiretroviral therapy cannot stop JC polyomavirus (JCV) replication, which causes progressive multifocal leukoencephalopathy (PML). Interferon (IFN) inhibits JCV replication, suggesting intrathecal IFN as a potential adjunctive therapy for PML.
Area of Science:
- Neurovirology
- Immunology
- Antiviral Therapy
Background:
- Highly active antiretroviral therapy (HAART) is ineffective against JC polyomavirus (JCV) replication.
- JCV causes progressive multifocal leukoencephalopathy (PML), an AIDS-defining illness.
- Previous studies showed JCV induces interferon-stimulated genes (ISGs).
Purpose of the Study:
- To identify viral events triggering ISG induction by JCV.
- To evaluate type I interferon's antiviral effects on JCV replication in human fetal glial cells.
- To assess the potential of interferon as an adjunctive therapy for PML.
Main Methods:
- Characterization of specific JCV replication steps inducing ISGs.
- Treatment of human fetal glial cells with type I interferons (IFNs) during JCV infection.
- Neutralization of IFN activity with specific antibodies to assess its antiviral role.
Main Results:
- Productive JCV replication is essential for inducing the antiviral host response (ISGs).
- Type I IFN significantly inhibited JCV replication across all viral life cycle stages.
- Neutralizing anti-IFN antibodies restored JCV replication, confirming IFN's direct antiviral effect.
Conclusions:
- JCV replication is susceptible to type I IFN-mediated inhibition.
- Interferon demonstrates potential as an adjunctive therapy for progressive multifocal leukoencephalopathy (PML).
- Intrathecal administration of IFN is recommended due to its inability to cross the blood-brain barrier.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release
Cytomegalovirus Disease
Encephalitis ll: Pathophysiology
Arboviral Encephalitis

